Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT02499328 |
TitleStudy to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck | Phase
Phase 1, Phase 2
|
Date Added 2015-07-16 |
Location
Alabama, United States
California, United States Colorado, United States Florida, United States Indiana, United States Massachusetts, United States Michigan, United States Montana, United States New Jersey, United States Ohio, United States Texas, United States Virginia, United States Washington, United States Belgium Germany Italy Spain United Kingdom |
Prior IO Allowed No |
CRC-directed No |
Status
Completed
|
Drugs
AZD5069, AZD9150, MEDI4736, tremelimumab (treme) |
Tags
MSS/ MMRp
|
| NCT ID NCT06107413 |
TitleStudy to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab | Phase
Phase 2
|
Date Added 2023-10-30 |
Location
Arizona, United States
Arkansas, United States California, United States Connecticut, United States Florida, United States Illinois, United States Indiana, United States Louisiana, United States Minnesota, United States North Carolina, United States Oregon, United States South Carolina, United States South Dakota, United States Texas, United States Virginia, United States Belgium Germany Israel Japan South Korea Spain Taiwan |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
ABBV-400, Bevacizumab, fluorouracil, Folinic acid, Irinotecan |
Tags
MSS/ MMRp
|
| NCT ID NCT05425940 |
TitleStudy of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (STELLAR-303) | Phase
Phase 3
|
Date Added 2022-06-21 |
Location
Alabama, United States
Arizona, United States California, United States Connecticut, United States Florida, United States Georgia, United States Illinois, United States Indiana, United States Kansas, United States Kentucky, United States Louisiana, United States Missouri, United States Montana, United States Nebraska, United States New Mexico, United States New York, United States North Carolina, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Virginia, United States Washington, United States Australia Belgium France Germany Hong Kong Hungary New Zealand Poland Portugal Singapore South Korea Spain Taiwan Thailand United Kingdom |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Atezolizumab (MPDL3280A), an Engineered Anti-PD-L1 Antibody, Regorafenib, XL092, Stivarga, Tecentriq |
Tags
MSS/ MMRp
|
| NCT ID NCT05784688 |
TitleStudy of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Phase
Phase 1, Phase 2
|
Date Added 2023-03-27 |
Location
Texas, United States
Washington, United States Korea, Republic of |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
TU2218 + Pembrolizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT03835949 |
TitleStudy of TJ004309 in Combination With Atezolizumab (Tecentriq(R)) in Patients With Advanced or Metastatic Cancer | Phase
Phase 1
|
Date Added 2019-02-11 |
Location
Alabama, United States
Arizona, United States California, United States Texas, United States |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Atezolizumab, TJ004309 |
Tags
MSS/ MMRp
|
| NCT ID NCT05350917 |
TitleStudy of Tislelizumab Combined With DisitamabVedotin and Pyrotinib Maleate in HER2-positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy | Phase
Phase 2
|
Date Added 2022-04-28 |
Location |
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs
Tislelizumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03865082 |
TitleStudy of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) | Phase
Phase 2
|
Date Added 2019-03-06 |
Location
Arizona, United States
California, United States Texas, United States |
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Ipilimumab, Nivolumab, Tilsotolimod, Opdivo, Yervoy |
Tags
MSS/ MMRp
|
| NCT ID NCT02869217 |
TitleStudy of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | Phase
Phase 1
|
Date Added 2016-08-16 |
Location
Canada
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Cyclophosphamide, Fludarabine, TBI-1301 |
Tags
MSS/ MMRp
|
| NCT ID NCT03223779 |
TitleStudy of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer | Phase
Phase 1, Phase 2
|
Date Added 2017-07-21 |
Location
Massachusetts, United States
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT03711058 |
TitleStudy of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer | Phase
Phase 1, Phase 2
|
Date Added 2018-10-18 |
Location
Maryland, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Completed
|
Drugs
Copanlisib, Nivolumab |
Tags
MSS/ MMRp
|
